Medical robotics company Clarapath recently secured $36 million in a Series B-1 funding round, led by Northwell Ventures. With this latest injection of capital, the company’s total funding has reached $75 million. New investors included Ochsner Ventures, CU Healthcare Innovation Fund, and Mayo Clinic. Based in New York, Clarapath has developed SectionStar, an autonomous AI-driven robotic system for tissue sectioning and transfer designed to enhance the operational efficiency of pathology labs. As SectionStar awaits its U.S. launch, the funding is earmarked for accelerating commercialization, as well as boosting research, development, manufacturing, services, and sales capacities.
Dr. Joaquín García of Mayo Clinic highlighted the goal to establish a highly automated, future-ready lab environment incorporating AI and robotics to optimize the handling and analysis of patient tissues. ReviR Therapeutics, a biotechnology firm focusing on AI-powered discovery of small molecule RNA modulators for neurogenetic diseases, has raised $30 million in a Series A financing round (total funding: $54 million). The round was led by Lapam Capital and saw participation from several other firms, including the Charcot-Marie Tooth Research Foundation. Funds will advance their drug discovery platform, VoyageR, targeting treatments for conditions such as ALS and Huntington’s disease.
RetiSpec, specializing in AI-driven eye diagnostics correlating to brain health, secured $10 million in its Series A round, bringing its total funding up to $17 million. This round included contributions from Eli Lilly and Topcon Healthcare, among others. The Canadian company is working on a diagnostic test that predicts the amyloid burden, a key biomarker for Alzheimer’s disease, which is currently available only for research purposes. The new funding will aid in accelerating the technology’s path to commercial use and clinical integration. Eliav Shaked, RetiSpec’s cofounder and CEO, expressed the financing round marks significant progress toward broadening the early detection of neurodegenerative diseases using their innovative eye test.
SoundHealth, based in San Francisco, announced a $7 million seed funding round for its AI-enabled medical device, SONU, and accompanying app. This funding, led by J4 Ventures and Moai Capital, will support the product launch and further development. SONU, which has received FDA De Novo classification, is a wearable device for adults experiencing nasal congestion due to rhinitis. The device operates by delivering acoustic vibrational energy to sinus and nasal areas, aiming to alleviate congestion. Paramesh Gopi, founder and CEO of SoundHealth, stated that the funding would advance their mission of providing personalized wearables for improved breathing and sleep.
#Robotics #company #Clarapath #raises #36M #digital #health #fundings
